TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26778629

Group type: EXPERIMENTAL
Intervention: 10Hz rTMS over the left dorsolateral prefrontal cortex
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 35
Study: 24112717

Group type: EXPERIMENTAL
Intervention: Experimental group with programmed parameters including higher detection rates, longer detection intervals, empiric antitachycardia pacing (ATP), and optimized supraventricular tachycardia (SVT) discriminators.
Number of subjects: 1670

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 1670

Group type: COMPARATOR
Intervention: Control group with conventional parameters.
Number of subjects: 1670

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1670
Study: 22782416

Group type: EXPERIMENTAL
Intervention: Fluorouracil plus folinic acid (20 mg/m2 of folinic acid via IV bolus followed by 425 mg/m2 of fluorouracil via IV bolus, administered 1 to 5 days every 28 days)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m2 IV infusion once a week for 3 of every 4 weeks for 6 months)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 428
Study: 20025837

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 1623

Group type: COMPARATOR
Intervention: No MRI
Number of subjects: 1623
Study: 16829196

Group type: EXPERIMENTAL
Intervention: Oral cryotherapy (holding ice cubes in the oral cavity before, during, and after 5FU infusion)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no oral cryotherapy)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Oral cryotherapy
Number of subjects: 76
Study: 15854177

Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Malic acid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Citric acid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ascorbic acid followed by citric acid
Number of subjects: 12
Study: 12362144

Group type: EXPERIMENTAL
Intervention: Support from non-professional volunteers
Number of subjects: 2

Group type: COMPARATOR
Intervention: Conventional child health services
Number of subjects: 2
Study: 9883001

Group type: EXPERIMENTAL
Intervention: Sumatriptan associated chest pain (cases)
Number of subjects: 129

Group type: COMPARATOR
Intervention: No chest pain after sumatriptan (controls)
Number of subjects: 129
Study: 7878172

Group type: EXPERIMENTAL
Intervention: Active group (could press a switch to stop the noise)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Passive group (yoked passive subjects received the same noises with no control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (yoked control group heard a soft tone following cue offset)
Number of subjects: 0
Study: 2368892

Group type: COMPARATOR
Intervention: Lignocaine 2% with adrenaline 1:200,000 plus normal saline 0.01 ml/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lignocaine 2% with adrenaline 1:200,000 plus fentanyl 1.0 microgram/kg
Number of subjects: 30
Study: 30797535

Group type: EXPERIMENTAL
Intervention: PrAISED 2 intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28279168

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 210
Study: 25776532

Group type: EXPERIMENTAL
Intervention: Early, goal-directed therapy (EGDT) - a 6-hour resuscitation protocol
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: EGDT
Number of subjects: 1260
Study: 25885732

Group type: EXPERIMENTAL
Intervention: Traditional nasal packing (Group NP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Uncuffed endotracheal tube (UA group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Bilateral nasal airway (BA group)
Number of subjects: 90
Study: 21853765

Group type: EXPERIMENTAL
Intervention: Aerobic training program (gymnastics, dancing, walking) for 8 weeks, 3 days per week
Number of subjects: 82

Group type: COMPARATOR
Intervention: Traditional pharmacotherapy (Fluoxetine 20 mg)
Number of subjects: 82
Study: 19905952

Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Plastic curet
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Metal curet
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Air-powder abrasive system
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (untreated specimens)
Number of subjects: 80
Study: 16713457

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 31
Study: 15016027

Group type: EXPERIMENTAL
Intervention: 1.5% SLS-containing dentifrice and 0.2% CHX mouthrinse (regimen 1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 0.2% CHX mouthrinse only (regimen 2)
Number of subjects: 16
Study: 11336164

Group type: EXPERIMENTAL
Intervention: IL‐1beta (10 ng/ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL‐1alpha, IL‐1beta, TNF, PMA, LPS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TNF and IL‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ALLN (proteasome and NF‐kappaB activation inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL‐4 and IL‐10
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control patients vs patients with mucosal inflammation
Number of subjects: 0
Study: 9124069

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAAs)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Flavoured water (placebo)
Number of subjects: 7
Study: 7653743

Group type: EXPERIMENTAL
Intervention: 2% sodium cromoglycate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3030090

Group type: EXPERIMENTAL
Intervention: 10% sucrose addition to cooked dried butter beans
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 20% sucrose addition to cooked dried butter beans
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 30% sucrose addition to cooked dried butter beans
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no sucrose addition)
Number of subjects: 40
Study: 30581161

Group type: EXPERIMENTAL
Intervention: Prophylactic entecavir (ETV) before chemotherapy and at least 6 months after completion of chemotherapy
Number of subjects: 190

Group type: COMPARATOR
Intervention: Regular monitoring alone (control)
Number of subjects: 190
Study: 29176824

Group type: EXPERIMENTAL
Intervention: Freeze-dried trivalent antivenom (FDTAV)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard liquid antivenom (SLAV)
Number of subjects: 116
Study: 26160997

Group type: EXPERIMENTAL
Intervention: Active TMS (10 sessions of 10 Hz rTMS at 110% of motor threshold, 2,000 pulses per session)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham TMS (control group)
Number of subjects: 34
Study: 23150919

Group type: EXPERIMENTAL
Intervention: Bendamustine 90 mg/m² plus Bortezomib 1.0 mg/m²
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bendamustine 50, 70, or 90 mg/m² plus Bortezomib 1.0 mg/m²
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bendamustine plus Bortezomib
Number of subjects: 40
Study: 21214899

Group type: EXPERIMENTAL
Intervention: Exhale® Drug‐Eluting Stent
Number of subjects: 450

Group type: COMPARATOR
Intervention: Sham bronchoscopy
Number of subjects: 450
Study: 18957146

Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuvers (RMs) performed twice daily for 3 days, starting at 35 cm H(2)O for 20 seconds, with potential increases to 40 cm H(2)O and 45 cm H(2)O or longer durations (30 seconds, then 40 seconds) if needed.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Scheduled lung recruitment maneuvers (RMs)
Number of subjects: 28
Study: 16581613

Group type: EXPERIMENTAL
Intervention: Antioxidants (combination tablet of vitamins A, C, and E)
Number of subjects: 798

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 798
Study: 15023671

Group type: EXPERIMENTAL
Intervention: High dairy protein (DP, 2400mg Ca/d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: High mixed protein (MP, 500mg Ca/d)
Number of subjects: 50
Study: 10955434

Group type: EXPERIMENTAL
Intervention: 25 mg oestradiol implants
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 50 mg oestradiol implants
Number of subjects: 44
Study: 8624267

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil 500 mg m‐2, epidoxorubicin 120 mg m‐2, cyclophosphamide 500 mg m‐2 (FE120C) administered at 21 day intervals without haematopoietic growth factors
Number of subjects: 70
Study: 1361718

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blocker treatment
Number of subjects: 0
Study: 6426493

Group type: EXPERIMENTAL
Intervention: Atracurium 0.45 mg kg‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pancuronium 0.1 mg kg‐1
Number of subjects: 20
Study: 27387971

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (2 μg/kg; maximum, 100 μg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous morphine (0.1 mg/kg; maximum, 8 mg)
Number of subjects: 20
Study: 29652460

Group type: EXPERIMENTAL
Intervention: Computer-controlled injection system
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional syringe
Number of subjects: 60
Study: 25899007

Group type: EXPERIMENTAL
Intervention: OBE001 600 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Betamethasone 12 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: OBE001 and Betamethasone combination
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 12
Study: 23964387

Group type: EXPERIMENTAL
Intervention: Zinc supplementation for 6 months
Number of subjects: 691

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 691
Study: 21904204

Group type: EXPERIMENTAL
Intervention: Peginterferon α‐2a (40 KD) 180 µg/week plus ribavirin (800 mg/day) for 24 weeks
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Peginterferon α‐2a (40 KD) 180 µg/week plus ribavirin (1000/1200 mg/day) for 48 weeks
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Overall treatment with peginterferon α‐2a (40 KD) plus ribavirin
Number of subjects: 789
Study: 18928387

Group type: EXPERIMENTAL
Intervention: Gelatin-sealant-assisted tubeless PCNL
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tubeless PCNL without gelatin
Number of subjects: 50
Study: 17220050

Group type: EXPERIMENTAL
Intervention: Clopidogrel (single oral dose) under fed condition (after a standardized high fat breakfast)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel (single oral dose) under fasted condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel (single oral dose) under fed condition
Number of subjects: 0
Study: 15626006

Group type: EXPERIMENTAL
Intervention: Surgical cricothyrotomy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Percutaneous cricothyrotomy
Number of subjects: 22
Study: 10686371

Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 0
Study: 9088811

Group type: EXPERIMENTAL
Intervention: Esmolol 4.0 mg kg‐1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate 7.5 micrograms kg‐1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 40 mg kg‐1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lignocaine 1.5 mg kg‐1
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 100
Study: 7515193

Group type: EXPERIMENTAL
Intervention: 3 x 10(6) KIU aprotinin (1 x 10(6) as a loading dose before cardiopulmonary bypass, 1 x 10(6) in the priming volume and 2.5 x 10(5)/hour intraoperatively)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aprotinin (reduced dosage)
Number of subjects: 40
Study: 3528891

Group type: EXPERIMENTAL
Intervention: DDAVP intranasally starting at 30 micrograms per day increasing to 180 micrograms per day
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 29737802

Group type: EXPERIMENTAL
Intervention: Cinnamon (3 capsules of 500 mg each daily for 8 weeks)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Cinnamon
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 27130723

Group type: EXPERIMENTAL
Intervention: Acupuncture-like transcutaneous nerve stimulation (ALTENS)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 27
Study: 25346054

Group type: EXPERIMENTAL
Intervention: Placebo session (deceptive instructions regarding administration of an analgesic drug)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control session (truthful information about an inert substance)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Placebo session
Number of subjects: 30
Study: 22220591

Group type: EXPERIMENTAL
Intervention: Melatonin (3mg, p.o., n=13)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (n=5)
Number of subjects: 18
Study: 19762549

Group type: EXPERIMENTAL
Intervention: Access to a counselor
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Information about spiritual services
Number of subjects: 226
Study: 17868057

Group type: EXPERIMENTAL
Intervention: sirolimus
Number of subjects: 145
Study: 15685254

Group type: EXPERIMENTAL
Intervention: Tamoxifen ('Nolvadex') 20 mg/day
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Anastrozole ('Arimidex') 1 mg/day
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 11789790

Group type: EXPERIMENTAL
Intervention: Minimally invasive technique (group A)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Traditional technique (group B)
Number of subjects: 255
Study: 9433653

Group type: EXPERIMENTAL
Intervention: Grepafloxacin 400 mg, daily for 7 days
Number of subjects: 36
Study: 8438003

Group type: EXPERIMENTAL
Intervention: AIDS education unit
Number of subjects: 103

Group type: COMPARATOR
Intervention: No AIDS education unit (control group)
Number of subjects: 103
Study: 3803106

Group type: EXPERIMENTAL
Intervention: Urecholine (oral or subcutaneous)
Number of subjects: 108

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Intravenous fluids
Number of subjects: 108
Study: 29655971

Group type: EXPERIMENTAL
Intervention: Biopsychosocial model of violence risk assessment (including V-RISK-10, SRS, TC, HDL)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: HDL
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: SRS
Number of subjects: 348
Study: 27981956

Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy
Number of subjects: 0
Study: 23910821

Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation (PSI)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Traditional instrumentation (TI)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Patient-specific instrumentation (PSI) vs Traditional instrumentation (TI)
Number of subjects: 52
Study: 21489005

Group type: EXPERIMENTAL
Intervention: Heroin
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1015
Study: 19223546

Group type: EXPERIMENTAL
Intervention: High intake of DiMeIQx
Number of subjects: 2253

Group type: EXPERIMENTAL
Intervention: High intake of MeIQx
Number of subjects: 2253

Group type: COMPARATOR
Intervention: Low intake of DiMeIQx
Number of subjects: 2253

Group type: COMPARATOR
Intervention: Low intake of MeIQx
Number of subjects: 2253
Study: 15901655

Group type: EXPERIMENTAL
Intervention: Attended walker
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ignored walker
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attended configurations (canonical and scrambled)
Number of subjects: 0
Study: 12920411

Group type: EXPERIMENTAL
Intervention: Mirtazapine (30‐45 mg/d)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Sertraline (50‐150 mg/d)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Mirtazapine and Sertraline
Number of subjects: 345
Study: 10843485

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) with non-conjugated estrogens, mean duration of HRT was 25 months, starting on average 18 months after completed therapy for ovarian cancer.
Number of subjects: 31
Study: 9282183

Group type: EXPERIMENTAL
Intervention: Manipulation under Bier's block
Number of subjects: 30

Group type: COMPARATOR
Intervention: Plaster immobilization alone
Number of subjects: 30
Study: 7509399

Group type: EXPERIMENTAL
Intervention: Combination of 1:100,000 adrenaline and 5% ethanolamine injection
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 70
Study: 3300138

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Entonox
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Pethidine + Promazine
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Lumbar Epidural
Number of subjects: 170
Study: 30102447

Group type: EXPERIMENTAL
Intervention: Intra-articular delayed gadolinium-enhanced MRI of menisci (dGEMRIM)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Intra-articular delayed gadolinium-enhanced MRI of cartilage (dGEMRIC)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: T1 relaxation times for cartilage, lateral menisci, and medial menisci
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Comparison of dGEMRIM between different morphology sum scores
Number of subjects: 85
Study: 27497768

Group type: EXPERIMENTAL
Intervention: Naltrexone with yohimbine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Yohimbine alone
Number of subjects: 16
Study: 26341547

Group type: EXPERIMENTAL
Intervention: Inhalation of 200 μg beclomethasone dipropionate (BDP) in standard posture
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Inhalation of 200 μg beclomethasone dipropionate (BDP) in forward leaning posture
Number of subjects: 32
Study: 24083590

Group type: EXPERIMENTAL
Intervention: HHPG‐19K 60 μg/kg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HHPG‐19K 100 μg/kg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HHPG‐19K 200 μg/kg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Filgrastim (G‐CSF) 5 μg/kg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Negative control group
Number of subjects: 30
Study: 19365087

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 18844721

Group type: EXPERIMENTAL
Intervention: High-emollient body wash
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular bar cleanser
Number of subjects: 0
Study: 21511219

Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg/day
Number of subjects: 71

Group type: COMPARATOR
Intervention: High-dose clopidogrel 150 mg/day
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg/day (in carriers of CYP2C19*2)
Number of subjects: 71

Group type: COMPARATOR
Intervention: High-dose clopidogrel 150 mg/day (in carriers of CYP2C19*2)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg/day (in noncarriers of CYP2C19*2)
Number of subjects: 71

Group type: COMPARATOR
Intervention: High-dose clopidogrel 150 mg/day (in noncarriers of CYP2C19*2)
Number of subjects: 71
Study: 16191668

Group type: EXPERIMENTAL
Intervention: Buprenorphine and carbamazepine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Methadone and carbamazepine
Number of subjects: 26
Study: 11831540

Group type: COMPARATOR
Intervention: Retigabine (200, 400, 500, and 600 mg per day fixed doses; 700 mg per day titrated doses)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Retigabine (titrated doses up to 700 mg per day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Retigabine (multiple doses)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Retigabine (in white subjects)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Retigabine (in black subjects)
Number of subjects: 45
Study: 9702467

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg bd)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8309562

Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (IVIg)
Number of subjects: 13
Study: 2468912

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 0
Study: 29798776

Group type: EXPERIMENTAL
Intervention: Everolimus-Eluting Stents (EES)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Drug-Eluting Balloons (DEB)
Number of subjects: 309
Study: 26979849

Group type: EXPERIMENTAL
Intervention: Boston psychiatric rehabilitation approach (bpr)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Care as usual (cau)
Number of subjects: 156
Study: 25898343

Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Antidepressant Medication (ADM)
Number of subjects: 100
Study: 23407019

Group type: EXPERIMENTAL
Intervention: HFCWO
Number of subjects: 107

Group type: COMPARATOR
Intervention: PEP
Number of subjects: 107
Study: 20939913

Group type: EXPERIMENTAL
Intervention: Program led by a clinical pharmacist trained in motivational interviewing‐based behavioral counseling approaches and authorized to make BP medication changes
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Program led by a clinical pharmacist
Number of subjects: 5

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5
Study: 18632838

Group type: EXPERIMENTAL
Intervention: Headgear (HG) treatment initiated immediately
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group with only minor interceptive procedures
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Patients treated without extraction of teeth
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Subjects treated with extractions
Number of subjects: 68
Study: 17128523

Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12755838

Group type: EXPERIMENTAL
Intervention: Post-operative transarterial chemotherapy
Number of subjects: 0